Coldstream Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.34M Buy
38,522
+5,714
+17% +$333K 0.03% 255
2025
Q4
$1.77M Sell
32,808
-5,129
-14% -$247K 0.02% 312
2025
Q3
$1.71M Buy
37,937
+9,329
+33% +$436K 0.02% 338
2025
Q2
$1.32M Sell
28,608
-6,625
-19% -$325K 0.02% 358
2025
Q1
$2.15M Sell
35,233
-1,054
-3% -$61.4K 0.05% 233
2024
Q4
$2.05M Buy
36,287
+7,154
+25% +$400K 0.04% 238
2024
Q3
$1.53M Buy
29,133
+9,324
+47% +$437K 0.03% 281
2024
Q2
$823K Sell
19,809
-348
-2% -$15.6K 0.02% 369
2024
Q1
$1.09M Sell
20,157
-1,966
-9% -$100K 0.03% 309
2023
Q4
$1.14M Sell
22,123
-6,370
-22% -$334K 0.03% 269
2023
Q3
$1.65M Sell
28,493
-50,016
-64% -$3.06M 0.05% 190
2023
Q2
$5.02M Buy
78,509
+5,231
+7% +$351K 0.16% 94
2023
Q1
$5.08M Buy
73,278
+44,530
+155% +$3.14M 0.17% 94
2022
Q4
$2.07M Buy
+28,748
New +$2.17M 0.08% 160
2022
Q2
$1.74M Buy
22,623
+4,325
+24% +$329K 0.07% 156
2022
Q1
$1.34M Sell
18,298
-262
-1% -$17.6K 0.05% 208
2021
Q4
$1.16M Buy
18,560
+2,484
+15% +$146K 0.04% 226
2021
Q3
$969K Buy
16,076
+2,469
+18% +$163K 0.05% 180
2021
Q2
$909K Sell
13,607
-3,688
-21% -$240K 0.04% 211
2021
Q1
$1.09M Buy
17,295
+688
+4% +$42.8K 0.06% 167
2020
Q4
$1.03M Buy
16,607
+3,130
+23% +$192K 0.06% 162
2020
Q3
$812K Sell
13,477
-157
-1% -$9.45K 0.07% 158
2020
Q2
$802K Buy
13,634
+536
+4% +$32.1K 0.07% 156
2020
Q1
$730K Sell
13,098
-215
-2% -$13.1K 0.08% 133
2019
Q4
$854K Buy
13,313
+4,066
+44% +$233K 0.07% 159
2019
Q3
$468K Buy
9,247
+422
+5% +$19.8K 0.04% 200
2019
Q2
$400K Sell
8,825
-1,048
-11% -$48.8K 0.03% 217
2019
Q1
$471K Sell
9,873
-918
-9% -$45.7K 0.04% 197
2018
Q4
$561K Sell
10,791
-364
-3% -$19.6K 0.05% 188
2018
Q3
$693K Sell
11,155
-132
-1% -$7.83K 0.06% 179
2018
Q2
$625K Sell
11,287
-1,189
-10% -$64.2K 0.06% 177
2018
Q1
$790K Buy
12,476
+275
+2% +$17.7K 0.09% 144
2017
Q4
$748K Sell
12,201
-1,516
-11% -$94.8K 0.08% 155
2017
Q3
$874K Buy
13,717
+1,062
+8% +$62K 0.1% 118
2017
Q2
$705K Buy
12,655
+680
+6% +$37K 0.09% 137
2017
Q1
$651K Buy
11,975
+360
+3% +$19.7K 0.09% 130
2016
Q4
$679K Buy
11,615
+138
+1% +$7.54K 0.11% 106
2016
Q3
$619K Sell
11,477
-574
-5% -$36.9K 0.11% 107
2016
Q2
$886K Sell
12,051
-509
-4% -$36K 0.16% 102
2016
Q1
$802K Buy
12,560
+2,720
+28% +$172K 0.15% 94
2015
Q4
$677K Buy
9,840
+192
+2% +$12.7K 0.15% 89
2015
Q3
$571K Buy
9,648
+3,128
+48% +$198K 0.15% 95
2015
Q2
$434K Buy
6,520
+891
+16% +$58.7K 0.11% 99
2015
Q1
$363K Sell
5,629
-879
-14% -$55K 0.1% 99
2014
Q4
$384K Buy
6,508
+11
+0.2% +$620 0.11% 108
2014
Q3
$333K Sell
6,497
-125
-2% -$6.24K 0.09% 114
2014
Q2
$321K Buy
6,622
+994
+18% +$49K 0.09% 121
2014
Q1
$292K Sell
5,628
-146
-3% -$7.77K 0.09% 120
2013
Q4
$307K Sell
5,774
-564
-9% -$28.7K 0.1% 120
2013
Q3
$293K Sell
6,338
-263
-4% -$11.5K 0.1% 120
2013
Q2
$295K Buy
+6,601
New +$287K 0.1% 124

Other funds holding BMY

Coldstream Capital Management's BMY Position: Q1 2026 in Review

Coldstream Capital Management increased its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, buying an estimated $333K and bringing the position to 38,522 shares worth $2.34M. The position accounts for 0.03% of the portfolio, ranked #255.

Coldstream Capital Management first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.08M in Q1 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Coldstream Capital Management held 38,522 shares of Bristol-Myers Squibb worth $2.34M as of Q1 2026.
  • Coldstream Capital Management bought 5,714 Bristol-Myers Squibb shares in Q1 2026, an estimated $333K.
  • Bristol-Myers Squibb made up 0.03% of Coldstream Capital Management's portfolio in Q1 2026, its #255 holding.
  • Coldstream Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • Coldstream Capital Management's Bristol-Myers Squibb position peaked at $5.08M in Q1 2023.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.